Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Labar, D. R.
Right arrow Articles by Root, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Labar, D. R.
Right arrow Articles by Root, J.
NEUROLOGY 1994;44:1400
© 1994 American Academy of Neurology

High-dose intravenous lorazepam for the treatment of refractory status epilepticus

Douglas R. Labar, MD, PhD, Auslim Ali, RN and Jonathan Root, MD

Department of Neurology, Comprehensive Epilepsy Center, New York Hospital-Cornell Medical Center, New York, NY.

We treated nine refractory status epilepticus cases with high-dose intravenous lorazepam. We monitored the EEGs continuously, and lorazepam dosing was titrated to stop clinical and electrographic seizures. Lorazepam doses needed to terminate status epilepticus ranged from 0.3 to 9 mg/hr. Lorazepam did not cause hypotension. All patients survived. Outcome was complete recovery in two cases, moderate disability in four, and severe disability in three. These findings suggest high-dose intravenous lorazepam may be an effective alternative to pentobarbital for the treatment of severe status epilepticus.

Address correspondence and reprint requests to Dr. Douglas R. Labar, Comprehensive Epilepsy Center, New York Hospital-Cornell Medical Center, K-619, 525 East 68th Street, New York, NY 10021.

Received November 10, 1993. Accepted in final form January 26, 1994.




This article has been cited by other articles:


Home page
 Postgrad. Med. J.Home page
R Nandhagopal
Generalised convulsive status epilepticus: an overview
Postgrad. Med. J., November 1, 2006; 82(973): 723 - 732.
[Abstract] [Full Text] [PDF]

Home page
 Emerg. Med. J.Home page
A S Lockey
Emergency department drug therapy for status epilepticus in adults.
Emerg. Med. J., March 1, 2002; 19(2): 96 - 100.
[Abstract] [Full Text] [PDF]

Home page
 J Child NeurolHome page
S. Singhi, A. Murthy, P. Singhi, and M. Jayashree
Continuous Midazolam Versus Diazepam Infusion for Refractory Convulsive Status Epilepticus
J Child Neurol, February 1, 2002; 17(2): 106 - 110.
[Abstract] [PDF]

Home page
 J Child NeurolHome page
D. L. Gilbert, P. S. Gartside, and T. A. Glauser
Efficacy and Mortality in Treatment of Refractory Generalized Convulsive Status Epilepticus in Children: A Meta-Analysis
J Child Neurol, September 1, 1999; 14(9): 602 - 609.
[Abstract] [PDF]

Home page
 J Child NeurolHome page
S. Singhi, S. Banerjee, and P. Singhi
Refractory Status Epilepticus in Children: Role of Continuous Diazepam Infusion
J Child Neurol, January 1, 1998; 13(1): 23 - 26.
[Abstract] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by AAN Enterprises, Inc.